Current Status of Diagnostic and Prognostic Markers in Melanoma

  • Danielle Levine
  • David E. Fisher
Part of the Methods in Molecular Biology book series (MIMB, volume 1102)


Melanoma is the most life-threatening common form of skin cancer. While most cutaneous melanomas are cured by surgical resection, a minority will relapse locally, regionally, or distantly. Biomarkers have represented a focal point for research aimed at improving diagnostic accuracy as well as providing prognostic information that may help to guide therapeutic decisions. While systemic melanoma therapies were of extremely limited utility for patients with advanced disease in the past, two drugs have been approved the FDA within the past several years, and it is possible that they may provide even greater impact if employed earlier in the disease process. To optimally employ these therapies, prognostic biomarkers may offer significant value. This article reviews methodologies for both discovery and routine testing of melanoma biomarkers. It also focuses on specific commonly used markers, as well as approaches to studying their applications to specific clinical settings. As the armamentarium of melanoma drugs grows, it is hoped that specific biomarkers will aid in guiding the use of these agents for patients in the clinic.

Key words

Melanoma Biomarker Prognosis Epigenetic Proteomic 


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRefGoogle Scholar
  2. 2.
    Ak I, Stokkel MP, Bergman W, Pauwels EK (2000) Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment. Eur J Nucl Med 27:447–458PubMedCrossRefGoogle Scholar
  3. 3.
    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199–6206PubMedCrossRefGoogle Scholar
  4. 4.
    Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U et al (2007) Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17:393–399PubMedCrossRefGoogle Scholar
  5. 5.
    Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N et al (2002) UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 55:46–54PubMedCrossRefGoogle Scholar
  6. 6.
    Dummer R, Hauschild A (2008) Jost L Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii86–ii88PubMedCrossRefGoogle Scholar
  7. 7.
    Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ et al (2008) Follow-up schedules after treatment for malignant melanoma. Br J Surg 95:1401–1407PubMedCrossRefGoogle Scholar
  8. 8.
    Sabel MS, Liu Y, Lubman DM (2011) Proteomics in melanoma biomarker discovery: great potential, many obstacles. Int J Proteomics 2011:181890PubMedGoogle Scholar
  9. 9.
    Shi SR, Liu C, Taylor CR (2007) Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem 55(2):105–109PubMedCrossRefGoogle Scholar
  10. 10.
    Coons AH (1791) The development of immunohistochemistry. NY Acad Sci 177:5–9Google Scholar
  11. 11.
    Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847PubMedCrossRefGoogle Scholar
  12. 12.
    Battifora H, Skacel M, Skilton B, Pettay JD, Tubbs RR (2002) Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens. Appl Immunohistochem Mol Morphol 10:1–6Google Scholar
  13. 13.
    Horne BD, Carlquist JF, Cannon-Albright LA, Muhlestein JB, McKinney JT, Kolek MJ, Clarke JL, Anderson JL, Camp NJ (2006) High-resolution characterization of linkage disequilibrium structure and selection of tagging single nucleotide polymorphisms: application to the cholesteryl ester transfer protein gene. Ann Hum Genet 70(Pt 4):524–534PubMedCrossRefGoogle Scholar
  14. 14.
    Marvin LF, Roberts MA, Fay LB (2003) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clin Chim Acta 337(1–2):11–21PubMedCrossRefGoogle Scholar
  15. 15.
    de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Bröcker EB, Renard N, Eggermont AM, van Muijen GN, Ruiter DJ (2001) Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 193(1):13–20PubMedCrossRefGoogle Scholar
  16. 16.
    Utikal J, Schadendorf D, Ugurel S (2007) Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 298(10):469–477PubMedCrossRefGoogle Scholar
  17. 17.
    Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R (2009) Biomarkers in melanoma. Ann Oncol 20(Suppl 6):vi8–vi13PubMedCrossRefGoogle Scholar
  18. 18.
    Liu S, Kirschmeier P, Simon J, Seidel-Dugan C, Puhlmann M (2008) Prognostic and predictive molecular markers in cutaneous malignant melanoma: the first step toward personalized medicine. Curr Pharmacogenomics Person Med 6(4):272–294CrossRefGoogle Scholar
  19. 19.
    Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891–1896PubMedGoogle Scholar
  20. 20.
    Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK, NCCN melanoma panel (2009) Melanoma. J Natl Compr Canc Netw 7(3):250–275PubMedGoogle Scholar
  21. 21.
    Thompson JF, Shaw HM, Stretch JR, McCarthy WH, Milton GW (2003) The Sydney melanoma unit—a multidisciplinary melanoma treatment center. Surg Clin North Am 83(2):431–451PubMedCrossRefGoogle Scholar
  22. 22.
    Deichmann M, Kahle B, Moser K, Wacker J, Wüst K (2004) Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91(4):699–702PubMedGoogle Scholar
  23. 23.
    Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG (2008) Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 15(8):2206–2214PubMedCrossRefGoogle Scholar
  24. 24.
    Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ (2010) The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem 285(35):27487–27498PubMedCrossRefGoogle Scholar
  25. 25.
    Kruijff S, Hoekstra HJ (2012) The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol 38(4):281–285PubMedCrossRefGoogle Scholar
  26. 26.
    Bouwhuis MG, Suciu S, Kruit W, Salès F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Liénard D, Eggermont AM, Ghanem G (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. European Organisation for Research and Treatment of Cancer Melanoma Group. Eur J Cancer 47(3):361–368PubMedCrossRefGoogle Scholar
  27. 27.
    Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF (2012) A synopsis of serum biomarkers in cutaneous melanoma patients. Dermatol Res Pract 2012:260643Google Scholar
  28. 28.
    Dummer R, Panizzon R, Bloch PH, Burg G (2005) Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 210(1):39–44PubMedCrossRefGoogle Scholar
  29. 29.
    Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A (2008) Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 6(Suppl 1):S9–S14PubMedGoogle Scholar
  30. 30.
    Retsas S, Mastrangelo MJ (2007) Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. Semin Oncol 34(6):491–497PubMedCrossRefGoogle Scholar
  31. 31.
    Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO (2007) Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol 46(5):678–684PubMedCrossRefGoogle Scholar
  32. 32.
    Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8):2422–2428PubMedCrossRefGoogle Scholar
  33. 33.
    Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM (2010) Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 41(3):375–384, Epub 2009 Dec 11PubMedCrossRefGoogle Scholar
  34. 34.
    Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Comessatti MG (2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 12(4):325–334PubMedCrossRefGoogle Scholar
  35. 35.
    Väisänen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T (2011) A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol 42(8):1103–1111PubMedCrossRefGoogle Scholar
  36. 36.
    Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17(8):2417–2425PubMedCrossRefGoogle Scholar
  37. 37.
    Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue Q, Chen J, Gao DM (1998) Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogas-troenterology 45(22):1056–1061Google Scholar
  38. 38.
    Rey MC, Bonamigo RR, Cartell A, Furian R, Bonfá R, Bonfá R (2011) MMP-2 and TIMP-2 in cutaneous melanoma: association with prognostic factors and description in cutaneous metastases. Am J Dermatopathol 33(4):413–414PubMedCrossRefGoogle Scholar
  39. 39.
    Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C (2002) Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 197(2):179–187PubMedCrossRefGoogle Scholar
  40. 40.
    Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D (2000) Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 20(3B):2203–2207PubMedGoogle Scholar
  41. 41.
    Bougatef F, Menashi S, Khayati F, Naïmi B, Porcher R, Podgorniak MP, Millot G, Janin A, Calvo F, Lebbé C, Mourah S (2010) EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. PLoS One 5(8):e12265PubMedCrossRefGoogle Scholar
  42. 42.
    Kanekura T, Chen X (2010) CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 57(3):149–154PubMedCrossRefGoogle Scholar
  43. 43.
    van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C (1997) Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151(3):665–670PubMedGoogle Scholar
  44. 44.
    Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY, Chun KH (2012) Galectin-3 increases the motility of mouse melanoma cells by regulating MMP-1 expression. Exp Mol Med 44(6):387–393PubMedCrossRefGoogle Scholar
  45. 45.
    Chen T, Zhu J (2010) Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol 27(4):1185–1191PubMedCrossRefGoogle Scholar
  46. 46.
    Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R, Italian Melanoma Intergroup (IMI) (2006) Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res 16(4):317–323PubMedCrossRefGoogle Scholar
  47. 47.
    Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83(7):847–852PubMedCrossRefGoogle Scholar
  48. 48.
    Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37(13):1629–1634PubMedCrossRefGoogle Scholar
  49. 49.
    Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164(1):193–203PubMedCrossRefGoogle Scholar
  50. 50.
    de Souza CF, Morais AS, Jasiulionis MG (2012) Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2012:156068. Epub 2011 Oct 31Google Scholar
  51. 51.
    Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101(7):452–474PubMedCrossRefGoogle Scholar
  52. 52.
    Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195(5):530–536PubMedCrossRefGoogle Scholar
  53. 53.
    Niezabitowski A, Czajecki K, Rys J (1999) Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70(3):150–160PubMedCrossRefGoogle Scholar
  54. 54.
    Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI, Shyjan AW (1998) Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58:1515PubMedGoogle Scholar
  55. 55.
    Deeds J, Cronin F, Duncan LM (2000) Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol 31:1346PubMedCrossRefGoogle Scholar
  56. 56.
    Erickson LA, Letts GA, Shah SM, Shackelton JB, Duncan LM (2009) TRPM1 (Melastatin-1/MLSN1) mRNA expression in Spitz nevi and nodular melanomas. Mod Pathol 22(7):969–976PubMedCrossRefGoogle Scholar
  57. 57.
    Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ (2001) Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 19:568–576PubMedGoogle Scholar
  58. 58.
    Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE (2004) Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 64:509PubMedCrossRefGoogle Scholar
  59. 59.
    Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21:665PubMedCrossRefGoogle Scholar
  60. 60.
    Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117–122PubMedCrossRefGoogle Scholar
  61. 61.
    Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565–576PubMedCrossRefGoogle Scholar
  62. 62.
    Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O’Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99–103PubMedCrossRefGoogle Scholar
  63. 63.
    Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12(5):349–361PubMedCrossRefGoogle Scholar
  64. 64.
    Hillesheim PB, Slone S, Kelley D, Malone J, Bahrami S (2011) An immunohistochemical comparison between MiTF and MART-1 with Azure blue counterstaining in the setting of solar lentigo and melanoma in situ. J Cutan Pathol 38(7):565–569PubMedCrossRefGoogle Scholar
  65. 65.
    Nielsen PS, Riber-Hansen R, Steiniche T (2011) Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol 33(4):361–370PubMedCrossRefGoogle Scholar
  66. 66.
    Samija I, Lukac J, Marić-Brozić J, Buljan M, Alajbeg I, Kovacević D, Situm M, Kusić Z (2010) Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res 20(4):293–302PubMedCrossRefGoogle Scholar
  67. 67.
    Bosserhoff AK, Hein R, Bogdahn U, Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271(1):490–495PubMedCrossRefGoogle Scholar
  68. 68.
    Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Le Bricon T (2007) Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43(4):816–821PubMedCrossRefGoogle Scholar
  69. 69.
    Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A (2011) Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 32(6):1155–1161PubMedCrossRefGoogle Scholar
  70. 70.
    Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10(2):267–275PubMedCrossRefGoogle Scholar
  71. 71.
    Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW (2012) Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer 48(6):865–874PubMedCrossRefGoogle Scholar
  72. 72.
    Buljan M, Šitum M, Tomas D, Milošević M, Krušlin B (2011) Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol 25(10):1174–1181PubMedCrossRefGoogle Scholar
  73. 73.
    Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1):144–150PubMedCrossRefGoogle Scholar
  74. 74.
    Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20(1):102–107PubMedCrossRefGoogle Scholar
  75. 75.
    Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, Brümmer J (2004) CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 165(5):1781–1787PubMedCrossRefGoogle Scholar
  76. 76.
    Thies A, Moll I, Berger J, Wagener C, Brümmer J, Schulze HJ, Brunner G, Schumacher U (2002) CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20(10):2530–2536PubMedCrossRefGoogle Scholar
  77. 77.
    Watson-Hurst K, Becker D (2006) The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 5(10):1375–1382PubMedCrossRefGoogle Scholar
  78. 78.
    Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson G (2005) Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 115(2):367–375PubMedCrossRefGoogle Scholar
  79. 79.
    Kärnell R, Kågedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U (2000) The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 10(4):363–369PubMedCrossRefGoogle Scholar
  80. 80.
    Kvam E, Dahle J (2005) The pheomelanin precursor 5-S-cysteinyldopa protects melanocytes from membrane damage induced by ultraviolet A radiation. Cancer Lett 221(2):131–134PubMedCrossRefGoogle Scholar
  81. 81.
    Bánfalvi T, Boldizsár M, Gergye M, Gilde K, Kremmer T, Ottó S (2002) Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 8(3):183–187PubMedCrossRefGoogle Scholar
  82. 82.
    Slominski A, Zmijewski MA, Pawelek J (2012) L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 25(1):14–27PubMedCrossRefGoogle Scholar
  83. 83.
    Abaffy T, Duncan R, Riemer DD, Tietje O, Elgart G, Milikowski C, DeFazio RA (2010) Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process. PLoS One 5(11):e13813PubMedCrossRefGoogle Scholar
  84. 84.
    Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS (2012) Epigenetic biomarkers in skin cancer. Cancer LettGoogle Scholar
  85. 85.
    Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6(3):388–394PubMedCrossRefGoogle Scholar
  86. 86.
    McShane LM, Altman DG, Gion M, Clark GM, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235PubMedCrossRefGoogle Scholar
  87. 87.
    Schramm SJ, Mann GJ (2011) Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 10(8):1520–1528, Epub 2011 Jun 9. ReviewPubMedCrossRefGoogle Scholar
  88. 88.
    Pras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C (2008) Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol Rep 20:271–277Google Scholar
  89. 89.
    Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15:6987–6992PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Danielle Levine
    • 1
  • David E. Fisher
    • 1
  1. 1.Department of DermatologyMassachusetts General HospitalBostonUSA

Personalised recommendations